Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Bioxyne Limited ( (AU:BXN) ).
Bioxyne Limited has announced its dual listing on the Frankfurt Stock Exchange, aiming to engage with global investors and enhance its presence in the European market. This strategic move aligns with the company’s focus on Europe, supported by a recent supply agreement and the appointment of a European Investor Relations Specialist. The dual listing is expected to increase Bioxyne’s visibility and provide greater access to European investors, particularly in Germany, where the legal cannabis market is expanding rapidly.
More about Bioxyne Limited
Bioxyne Limited operates in the medicinal cannabis industry, focusing on the development and delivery of high-quality cannabis products. The company is engaged in the production of novel medicines, including cannabis, MDMA, and Psilocybin, with a market focus on Europe, particularly Germany, which is a rapidly growing legal cannabis market.
Average Trading Volume: 4,943,863
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$80.36M
See more insights into BXN stock on TipRanks’ Stock Analysis page.